In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA′ in a human acute myeloid leukemia xenograft tumor model

International Journal of Cancer

Volumn 129, Issue 5, 2011, Pages 1277-1282

  Tur, Mehmet Kemal ^a   Huhn, Michael ^a   Jost, Edgar ^a   Thepen, Theo ^b   Brümmendorf, Tim H ^a   Barth, Stefan ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

AML; CD64; in vivo efficacy; recombinant immunotoxin; targeted immunotherapy

Indexed keywords

CD64 ANTIGEN; IMMUNOTOXIN; RECOMBINANT H22 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY PSEUDOMONAS EXOTOXIN A IMMUNOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL KILLING; CELL PROLIFERATION; CELL STRAIN U937; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL TIME; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; EXOTOXINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTOXINS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; SURVIVAL RATE; TUMOR CELLS, CULTURED; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959712029     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25766     Document Type: Article

References (25)

1. Kennedy JA, Barabe F,. Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. Leukemia 2008; 22: 2029-40.
2. Stone RM, O'Donnell MR, Sekeres MA,. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004; 98-117.
3. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB,. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008; 26: 3777-84.
4. Morris JC, Waldmann TA,. Antibody-based therapy of leukaemia. Expert Rev Mol Med 2009; 11: e29 -.
5. Carter PJ, Senter PD,. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14: 154-69.
6. Kreitman RJ, Pastan I,. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 2006; 7: 1301-11. (Pubitemid 44509694)
7. Dunphy CH, Tang W,. The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. Arch Pathol Lab Med 2007; 131: 748-54. (Pubitemid 46726136)
8. Anderson CL,. Isolation of the receptor for IgG from a human monocyte cell line (U937) and from human peripheral blood monocytes. J Exp Med 1982; 156: 1794-1806. (Pubitemid 13167422)
9. Thepen T, Huhn M, Melmer G, Tur MK, Barth S,. Fcγ receptor 1 (CD64), a target beyond cancer. Curr Pharm Des 2009; 15: 2712-8.
10. Zhong RK, van de Winkel JG, Thepen T, Schultz LD, Ball ED,. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. J Hematother Stem Cell Res 2001; 10: 95-105. (Pubitemid 32233695)
11. Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, Engert A,. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003; 14: 729-36. (Pubitemid 36621773)
12. Kreitman RJ,. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009; 23: 1-13.
13. Tur MK, Huhn M, Thepen T, Stocker M, Krohn R, Vogel S, Jost E, Osieka R, van de Winkel JG, Fischer R, Finnern R, Barth S,. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 2003; 63: 8414-9. (Pubitemid 37549497)
14. Ribbert T, Thepen T, Tur MK, Fischer R, Huhn M, Barth S,. Recombinant, ETA′-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice. Br J Dermatol 2010; 163: 279-86.
15. Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S, Stocker M,. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother 2008; 31: 370-6. (Pubitemid 351595159)
16. Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, Santoli D,. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene 1992; 7: 827-36.
17. Schlenk RF, Dohner K,. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 2009; 16: 98-104.
18. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-18. (Pubitemid 351620111)
19. Robak T, Wierzbowska A,. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31 (Pt 2): 2349-70.
20. Kuo SR, Alfano RW, Frankel AE, Liu JS,. Antibody internalization after cell surface antigen binding is critical for immunotoxin development. Bioconjug Chem 2009; 20: 1975-82.
21. Maitta RW, Cannizzaro LA, Ramesh KH,. Association of MLL amplification with poor outcome in acute myeloid leukemia. Cancer Genet Cytogenet 2009; 192: 40-3.
22. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T, Diehl V, Engert A,. Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000; 95: 3909-14. (Pubitemid 30412867)
23. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I,. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 2008; 105: 11311-6.
24. Tur MK, Neef I, Jager G, Teubner A, Stocker M, Melmer G, Barth S,. Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy. Curr Pharm Des 2009; 15: 2693-9.
25. Stahnke B, Thepen T, Stocker M, Rosinke R, Jost E, Fischer R, Tur MK, Barth S,. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 2008; 7: 2924-32.